Cann Group (CAN.AX) Akcie Kurz
Cann Group Kurz
Tržby rostly o 79,5 % ročně za posledních 11 let na 8,56 Mil. AUD. čistá marže společnosti Cann Group je nyní 237,1 %, nahoru z -412,9 % před několika lety.
Cena akcie Cann Group
Obchodní model Cann Group a analýza akcií
Nejčastější otázky týkající se akcie Cann Group
Cann Group Ltd is an Australian company that operates in the medicinal cannabis industry. Its business model revolves around cultivation, manufacturing, and distribution of pharmaceutical-grade cannabis products and providing services to the medicinal cannabis sector. With a focus on research and development, Cann Group aims to support healthcare professionals and patients by developing high-quality therapeutic products derived from cannabis plants. The company's expertise lies in the production of standardized cannabis cultivars, extraction, and development of new formulations to meet the evolving needs of the medical industry. Cann Group Ltd strives to establish itself as a leading player in the medicinal cannabis market.
Cann Group Ltd is primarily active in the cannabis industry.
The main competitors of Cann Group Ltd in the market include other companies involved in the production and distribution of medical cannabis and cannabis-related products. Some significant competitors of Cann Group Ltd may include AusCann Group Holdings Ltd, Althea Group Holdings Ltd, and Little Green Pharma Ltd. These companies operate in the same industry and focus on the cultivation, manufacturing, and sale of medical cannabis products. Cann Group Ltd competes with these companies to gain market share, secure partnerships, and expand their customer base in the rapidly growing cannabis industry.
Cann Group Ltd is an Australian company that specializes in cultivating and producing medical cannabis. Established in 2014, Cann Group was the first to be granted a license to cultivate and research cannabis for medicinal purposes in Australia. With a strong commitment to quality and compliance, the company has built state-of-the-art facilities and established strategic partnerships to expand its operations. Cann Group is dedicated to providing safe and effective cannabis-based products to improve patient outcomes and is at the forefront of the rapidly growing medicinal cannabis industry in Australia.
Cann Group Ltd has achieved several significant milestones in its operations. Firstly, the company became the first Australian business to obtain a license to cultivate medicinal cannabis for research purposes in 2017. This achievement positioned Cann Group Ltd as a pioneer in the country's emerging medicinal cannabis industry. Additionally, the company successfully completed its first commercial cannabis harvest in 2018, marking another important milestone. Furthermore, Cann Group Ltd obtained its crucial Manufacture License in 2019, allowing the company to produce and distribute medicinal cannabis products in Australia. These milestones highlight Cann Group Ltd's commitment to advancing the availability and quality of medicinal cannabis within the country's market.
Cann Group Ltd is primarily present in Australia.
Cann Group Ltd, a leading Australian medicinal cannabis company, embodies a strong set of values and corporate philosophy. The company is committed to producing high-quality medical cannabis products to improve the lives of patients. Cann Group values innovation and sustainability, constantly seeking new ways to enhance their cultivation and manufacturing processes. With a focus on research and development, they aim to continually expand their product offerings and provide effective and safe treatments. Cann Group Ltd prides itself on its dedication to investors, transparency, and regulatory compliance, ensuring a trustworthy and reliable approach to business.
5 analytiků aktuálně hodnotí akcii Cann Group: 4 doporučuje koupit, 1 držet a 0 prodat.
Při aktuálním kurzu se akcie Cann Group obchoduje za 0,00 EUR (0,01 AUD).
Akcie Cann Group (CAN.AX) je kótována na 3 burzách, mimo jiné: ASX (CAN.AX), Frankfurt (CVJ.F).
Cann Group Ltd is an Australian company specializing in the medical cannabis market. Its business model involves producing, developing, and distributing cannabis for medical use. The company serves various segments, such as the market for human medical products, the veterinary sector, and the recreational and wellness sector. The company is well positioned to benefit from the growing demand for medical cannabis, CBD products for pets, and recreational products.
Tržby za Cann Group činí 8,56 Mil. AUD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk za Cann Group činí 20,30 Mil. AUD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Cann Group je aktuálně 0,36. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Cann Group.
Poměr ceny k tržbám (P/S) Cann Group je aktuálně 0,85. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Cann Group.
Score kvality pro Cann Group je 3/10.
ISIN Cann Group je AU000000CAN2. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Cann Group je A2DSUQ. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Cann Group je CAN.AX. Symbol tickeru se používá k obchodování akcií Cann Group na burze.
Cann Group akcie
Cann Group Peer Group
Cann Group Ticker
Cann Group FIGI
Všechny fundamentální údaje o Cann Group v podrobné analýze
Naše analýzy akcií společnosti Cann Group zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Cann Group. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: